BioCryst Pharmaceuticals, Inc. is a company in the U.S. stock market and it is a holding in 34 U.S.-traded ETFs. BCRX has around 23.2M shares in the U.S. ETF market. The largest ETF holder of BCRX is the SPDR S&P Biotech ETF (XBI), with approximately 13.28M shares. Investors may also find of interest that the ETF with the largest allocation to BCRX stock is ETFMG Treatments Testing and Advancements ETF (GERM), with a portfolio weight of 1.14%. On average, U.S. ETFs allocate 0.15% of BCRX to their portfolios.
Additionally, BCRX is a favorite stock for Vanilla and Equal ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with BCRX as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 48.59%.